Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies
Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
C Shi, Y Wang, J Xue, X Zhou - Frontiers in Immunology, 2022 - frontiersin.org
Immune checkpoint inhibitors (ICIs) are effective against advanced and even perioperative
non-small-cell lung cancer (NSCLC) and result in durable clinical benefit, regardless of …
non-small-cell lung cancer (NSCLC) and result in durable clinical benefit, regardless of …
Afatinib for the treatment of nsclc with uncommon egfr mutations: A narrative review
Y Jiang, X Fang, Y Xiang, T Fang, J Liu, K Lu - Current Oncology, 2023 - mdpi.com
Afatinib, the world's first irreversible ErbB family (containing four different cancer cell
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li, Y Xu… - Bmc Cancer, 2023 - Springer
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
[HTML][HTML] Multiple mutations in the EGFR gene in lung cancer: a systematic review
JP Castañeda-González, JJ Chaves… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background Lung cancer is a public health problem worldwide. Currently, identifying genetic
mutations in the epidermal growth factor receptor (EGFR) has brought significant changes in …
mutations in the epidermal growth factor receptor (EGFR) has brought significant changes in …
Dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon EGFR alterations: a dual-center, single-arm, ambispective cohort study in …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu, T Zhang… - Frontiers in …, 2022 - frontiersin.org
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
[HTML][HTML] Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain …
Background and objective Epidermal growth factor receptor (EGFR)–targeted tyrosine
kinase inhibitors (TKIs) are the first-line therapy for EGFR-mutant non-small-cell lung cancer …
kinase inhibitors (TKIs) are the first-line therapy for EGFR-mutant non-small-cell lung cancer …
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
D Yan - Biomedicines, 2023 - mdpi.com
EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell
lung cancer (NSCLC) patients harboring sensitive EGFR mutations. Sadly, remission is …
lung cancer (NSCLC) patients harboring sensitive EGFR mutations. Sadly, remission is …
Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis
S Van Sanden, M Murton, A Bobrowska, N Rahhali… - Targeted Oncology, 2022 - Springer
Background Information on the epidemiology of uncommon EGFR mutations including exon
20 insertions amongst non-small-cell lung cancer (NSCLC) is lacking. Objective The …
20 insertions amongst non-small-cell lung cancer (NSCLC) is lacking. Objective The …
Emerging paradigms and recent progress in targeting ErbB in cancers
N Stoup, M Liberelle, N Lebègue… - Trends in …, 2024 - cell.com
The epidermal growth factor receptor (EGFR) family is a class of transmembrane proteins,
highly regarded as anticancer targets due to their pivotal role in various malignancies …
highly regarded as anticancer targets due to their pivotal role in various malignancies …